+91-8668442535

Wilson’s Disease Drugs Market By Indication (Hepatic, Neuropsychiatric, Ophthalmic And Others), By Drug Class (Chelators, Minerals, Pipeline Analysis) - Growth, Future Prospects & Competitive Analysis, 2017 – 2025

Wilson's disease occurs equally in both male and female populations, but research studies have cited differences in the sex-specific phenotypes. Hepatic symptoms occur 55%–60% more often in the female population. Frank psychosis is more prevalent in the male population and is often mistaken for bipolar disorder or schizophrenia. In the near future, gene therapy can be used to transfer the ATPB7 gene if sufficient amounts of the transgene are expressed in the liver cells for a longer period of time. It is very important for the accurate diagnosis of Wilson's disease, which could have fatal consequences if not done appropriately.

The early diagnosis of Wilson's disease is primarily based on multiple indications, such as hepatic, neuropsychiatric, ophthalmic, and others. The chelators are the first line of therapy, which includes penicillamine and trientine. Zinc acetate is considered the only mineral prescribed for patients who are resistant to chelator therapy. Data mining and market estimation are covered in the scope of the report to understand the opportunity for novel drug discovery in the treatment of Wilson's disease.

Market estimation and data mining are helpful in understanding the current treatment regimen and regulatory norms prevalent in different geographical regions.

An attractive investment proposition gives a genuine understanding of the disease prevalence in different countries through data mining and the approach adopted to consider the treatment regimen for Wilson's disease. The product portfolio gives an idea of the different dietary supplements enriched in zinc primarily used for the management of Wilson's disease. Recent news coverage sheds light on the strategic collaboration taking place in the healthcare sector to launch novel drug discovery for the treatment of Wilson's disease. The manufacturers that are active in the treatment of Wilson's disease are Kadmon Holdings, Inc., Merck & Co., Noble Pharma Co., Ltd., Teva Pharmaceutical Industries Limited, Tsumura & Co., Valeant Pharmaceuticals International, Inc., VHB Life Sciences, Inc., and Wilson Therapeutics AB.

Based on indications, the global Wilson's disease drugs market is categorized into

  • Hepatic
  • Neuropsychiatric
  • Ophthalmic
  • Others (heart and kidney complications)

Wilson's disease is a rare hereditary disorder that occurs due to the accumulation of copper in different body organs such as the liver, brain, eyes, and other vital organs. The disease takes place due to a mutation in the ATP7B gene. The prevalence rate of Wilson's disease is 1 in 30,000 persons; it is usually diagnosed in the young and adult age groups. Hepatic indications are first diagnosed in the disease manifestation of Wilson's disease on account of reduced biliary excretion of copper, which results in excessive accumulation of copper in the liver. The early symptoms manifested in liver indications are tiredness and hepatitis with elevated levels of gamma-glutamyl transpeptidase, alanine aminotransferase, and aspartate aminotransferase. The neuropsychiatric symptoms manifest in the later stages of the disease's manifestation, with the basal ganglia hampering coordinated movement.

The major symptoms are Parkinsonism, tremors, ataxia, dystonia, and seizures. In approximately 90 percent of the patients exhibiting neuropsychiatric symptoms, the development of Kayser-Fleisher rings (deposition of copper) in the corneal region of the eyes is evident. The manufacturers that are active in the treatment of Wilson's disease are Kadmon Holdings, Inc., Merck & Co., Noble Pharma Co., Ltd., Teva Pharmaceutical Industries Limited, Tsumura & Co., Valeant Pharmaceuticals International, Inc., VHB Life Sciences, Inc., and Wilson Therapeutics AB.

Based on drug class, Wilson's disease drug market is categorized into:

Chelators

  • Penicillamine
  • Trientine

Minerals

  • Zinc Acetate

The primary diagnosis of Wilson's disease is complicated, as the symptoms are similar to those of other diseases, such as hepatitis C, seizures, jaundice, heavy metal poisoning, and cerebral palsy. Despite the fact that Wilson's disease is a hereditary genetic disease, a person is unlikely to acquire the ATPB7 mutation if only one abnormal gene is inherited from either parent. The management of the disease is entirely focused on compensating for the abnormal copper metabolism.

As if chelators are now the first line of treatment for Wilson's disease patients seeking symptomatic relief, Chelators deplete the excessive copper levels in the body by expediting their excretion through urine but being nonspecific to copper, they also bind and excrete other micronutrients from the body. The adverse effects related to chelators are severe, such as bone marrow suppression and kidney complications, thereby hampering their market growth. Zinc acetate is the only mineral recommended as an alternative therapy to chelators. It works by reducing the dietary uptake of copper in the gastrointestinal tract and excreting it through feces. Because its effects are extremely slow, it is only used for maintenance therapy.

For the purpose of this study, the global Wilson's disease drugs market is categorized into the following regional and country-specific markets:

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • Italy
    • U.K.
    • Russia
    • Rest of Europe
  • Asia-Pacific
    • India
    • China
    • Japan
    • Rest of Asia-Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • GCC Countries
    • South Africa
    • Rest of Middle East and Africa

According to the U.S. Department of Health and Human Services 2015 countrywide survey, the prevalence of Wilson's disease in the United States is 1 in 55,000 births, with an allele frequency rate of 0.00428. North America is the most significant market in Wilson's disease treatment drugs market on account of the high Wilson's disease heterozygote frequency rate of 0.855% in the Caucasian population. The autosomal recessive rate of Wilson's disease is approximately 25% in Europe, with patients being resistant to chelator therapy and the E.U. approving only zinc acetate for Wilson's disease management in Europe. Being an orphan disease, the European Medical Agency is proactively investing in novel drug discovery for Wilson's disease. The neuropsychiatric indications related to Wilson's disease are on the rise in Asia and the Pacific. The market is heavily dependent on treatment drugs imported from the U.S. and Europe, which creates a huge opportunity for the existing generic market in Asia-Pacific.

Frequently Asked Question:

The market for Wilson’s Disease Drugs Market is expected to reach USD$ 592.8 Mn in 2025.

The Wilson’s Disease Drugs Market is expected to see significant CAGR growth over the coming years, at 5.19%.

The report is forecasted from 2017 -2025.

The base year of this report is 2016.

Merck & Co., Noble Pharma Co., Ltd., Teva Pharmaceutical Industries Limited, Tsumura & Co., Valeant Pharmaceuticals International, Inc. are some of the major players in the global market.

Choose License Type
Trusted By
Godaddy
Published Date:  Jan 2018
Category:  Pharmaceuticals
Report ID:   58947
Report Format:   PDF
Pages:   120
Rating:    4.1 (44)
Delivery Time: 24 Hours to 48 Hours   
Connect With Us
+91-8668442535
24/7 Research Support